UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000042955
Receipt No. R000049007
Scientific Title Prospective observational study investigating clinical impact by using electronic patient-reported outcomes (ePRO) on the management of adverse events of chemotherapy
Date of disclosure of the study information 2021/01/12
Last modified on 2021/01/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective observational study investigating clinical impact by using electronic patient-reported outcomes (ePRO) on the management of adverse events of chemotherapy
Acronym Management of adverse events by using ePRO
Scientific Title Prospective observational study investigating clinical impact by using electronic patient-reported outcomes (ePRO) on the management of adverse events of chemotherapy
Scientific Title:Acronym Management of adverse events by using ePRO
Region
Japan

Condition
Condition Breast cancer
Classification by specialty
Hematology and clinical oncology Breast surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the clinical benefits by using ePRO in the management of adverse events during pharmacotherapy for breast cancer
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Percentage of unscheduled visits
Key secondary outcomes Compliance with inputting adverse events into the ePRO system

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1) Pathologically diagnosed as breast cancer
(2) Receiving systemic anticancer pharmacotherapy (e.g., cytotoxic anticancer agents, molecularly targeted drugs, and immune checkpoint inhibitors) for breast cancer
(3) Capable of using electronic devices
(4) Written consent for the study personally obtained from the subject
Key exclusion criteria (1) Difficulty in using electronic devices
(2) Receiving hormone therapy only
Target sample size 80

Research contact person
Name of lead principal investigator
1st name Tetsuhiko
Middle name
Last name Taira
Organization Sagara Hospital
Division name Department of Oncology
Zip code 892-0833
Address 3-31 Matsubara-cho, Kagoshima City
TEL 099-224-1800
Email ttaira-tt@sagara.or.jp

Public contact
Name of contact person
1st name Tetsuhiko
Middle name
Last name Taira
Organization Sagara Hospital
Division name Department of Oncology
Zip code 892-0833
Address 3-31 Matsubara-cho, Kagoshima City
TEL 099-224-1800
Homepage URL
Email ttaira-tt@sagara.or.jp

Sponsor
Institute Sagara Hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization HAKUAIKAI Social Medical Corporation
Address 3-31 Matsubara-cho, Kagoshima City
Tel 099-224-1800
Email ttaira-tt@sagara.or.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 01 Month 12 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2020 Year 04 Month 09 Day
Date of IRB
2020 Year 04 Month 21 Day
Anticipated trial start date
2020 Year 05 Month 07 Day
Last follow-up date
2021 Year 04 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Evaluate the clinical effects of using ePRO for side effect management of breast cancer pharmacotherapy, and then introduce ePRO into clinical practice.

Management information
Registered date
2021 Year 01 Month 09 Day
Last modified on
2021 Year 01 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049007

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.